Skip to main content
Erschienen in: Breast Cancer Research and Treatment 3/2011

01.10.2011 | Epidemiology

Genetic variants of 6q25 and breast cancer susceptibility: a two-stage fine mapping study in a Chinese population

verfasst von: Jing Han, Tao Jiang, Hongling Bai, Hongru Gu, Jing Dong, Hongxia Ma, Zhibin Hu, Hongbing Shen

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

A recent genome-wide association study identified a novel single nucleotide polymorphism (SNP), rs2046210, in the 6q25 region as a breast cancer susceptibility locus in Chinese and subsequently replicated in a multicenter study. Further fine-mapping of this region may help identify the potential causative SNPs of breast cancer. We employed a block-based fine mapping analysis to investigate the tagging SNPs in a 41 kb block with the marker-SNP rs2046210 in the 6q25 region, and also extended our study by including two potentially functional SNPs (rs2234693 and rs1801132) within the ESR1 gene by a two-stage case–control study with 1,792 breast cancer cases and 1,867 controls (878 cases and 900 controls in the testing set and 914 cases and 967 controls in the validation set). Significant associations with breast cancer risk were observed for rs1038304, rs6929137, rs2046210, and rs10484919 in the 41 kb block of the 6q25 region in the testing set after controlling multiple testing. Together with the validation set samples, these four SNPs were all significantly associated with increased risk of breast cancer (additive OR from 1.25 to 1.34, additive P from 4.84 × 10−6 to 7.17 × 10−9). After conditional regression and linkage disequilibrium analyses, rs6929137 and rs10484919 tend to be susceptible markers of breast cancer in this region and both of them were located at sites of histone modification according to the UCSC (http://​genome.​ucsc.​edu/​) genome database. Our results support that the 6q25 region is an important susceptibility region for breast cancer in Chinese women, and rs6929137 and rs10484919 are causative or marker SNPs for this region.
Literatur
1.
Zurück zum Zitat Nathanson KL, Wooster R, Weber BL (2001) Breast cancer genetics: what we know and what we need. Nat Med 7(5):552–556PubMedCrossRef Nathanson KL, Wooster R, Weber BL (2001) Breast cancer genetics: what we know and what we need. Nat Med 7(5):552–556PubMedCrossRef
2.
Zurück zum Zitat Easton DF et al (2007) Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 447(7148):1087–1093PubMedCrossRef Easton DF et al (2007) Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 447(7148):1087–1093PubMedCrossRef
3.
Zurück zum Zitat Hunter DJ et al (2007) A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet 39(7):870–874PubMedCrossRef Hunter DJ et al (2007) A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet 39(7):870–874PubMedCrossRef
4.
Zurück zum Zitat Stacey SN et al (2007) Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet 39(7):865–869PubMedCrossRef Stacey SN et al (2007) Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet 39(7):865–869PubMedCrossRef
5.
Zurück zum Zitat Gold B et al (2008) Genome-wide association study provides evidence for a breast cancer risk locus at 6q22.33. Proc Natl Acad Sci USA 105(11):4340–4345PubMedCrossRef Gold B et al (2008) Genome-wide association study provides evidence for a breast cancer risk locus at 6q22.33. Proc Natl Acad Sci USA 105(11):4340–4345PubMedCrossRef
6.
Zurück zum Zitat Zheng W et al (2009) Genome-wide association study identifies a new breast cancer susceptibility locus at 6q25.1. Nat Genet 41(3):324–328PubMedCrossRef Zheng W et al (2009) Genome-wide association study identifies a new breast cancer susceptibility locus at 6q25.1. Nat Genet 41(3):324–328PubMedCrossRef
7.
Zurück zum Zitat Thomas G et al (2009) A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nat Genet 41(5):579–584PubMedCrossRef Thomas G et al (2009) A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nat Genet 41(5):579–584PubMedCrossRef
8.
Zurück zum Zitat Ahmed S et al (2009) Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat Genet 41(5):585–590PubMedCrossRef Ahmed S et al (2009) Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat Genet 41(5):585–590PubMedCrossRef
9.
Zurück zum Zitat Stacey SN et al (2008) Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet 40(6):703–706PubMedCrossRef Stacey SN et al (2008) Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet 40(6):703–706PubMedCrossRef
10.
Zurück zum Zitat Turnbull C et al (2010) Genome-wide association study identifies five new breast cancer susceptibility loci. Nat Genet 42(6):504–507PubMedCrossRef Turnbull C et al (2010) Genome-wide association study identifies five new breast cancer susceptibility loci. Nat Genet 42(6):504–507PubMedCrossRef
11.
Zurück zum Zitat Cai Q et al (2011) Replication and functional genomic analyses of the breast cancer susceptibility locus at 6q25.1 generalize its importance in women of Chinese, Japanese, and European Ancestry. Cancer Res 71:1344–1355PubMedCrossRef Cai Q et al (2011) Replication and functional genomic analyses of the breast cancer susceptibility locus at 6q25.1 generalize its importance in women of Chinese, Japanese, and European Ancestry. Cancer Res 71:1344–1355PubMedCrossRef
12.
Zurück zum Zitat Key T et al (2002) Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 94(8):606–616PubMed Key T et al (2002) Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 94(8):606–616PubMed
13.
Zurück zum Zitat Khan SA et al (1998) Estrogen receptor expression in benign breast epithelium and breast cancer risk. J Natl Cancer Inst 90(1):37–42PubMedCrossRef Khan SA et al (1998) Estrogen receptor expression in benign breast epithelium and breast cancer risk. J Natl Cancer Inst 90(1):37–42PubMedCrossRef
14.
Zurück zum Zitat Li N et al (2010) Potentially functional polymorphisms in ESR1 and breast cancer risk: a meta-analysis. Breast Cancer Res Treat 121(1):177–184PubMedCrossRef Li N et al (2010) Potentially functional polymorphisms in ESR1 and breast cancer risk: a meta-analysis. Breast Cancer Res Treat 121(1):177–184PubMedCrossRef
15.
Zurück zum Zitat Styrkarsdottir U et al (2008) Multiple genetic loci for bone mineral density and fractures. N Engl J Med 358(22):2355–2365PubMedCrossRef Styrkarsdottir U et al (2008) Multiple genetic loci for bone mineral density and fractures. N Engl J Med 358(22):2355–2365PubMedCrossRef
16.
Zurück zum Zitat Gabriel SB et al (2002) The structure of haplotype blocks in the human genome. Science 296(5576):2225–2229PubMedCrossRef Gabriel SB et al (2002) The structure of haplotype blocks in the human genome. Science 296(5576):2225–2229PubMedCrossRef
17.
Zurück zum Zitat Gonzalez JR et al (2007) SNPassoc: an R package to perform whole genome association studies. Bioinformatics 23(5):644–645PubMedCrossRef Gonzalez JR et al (2007) SNPassoc: an R package to perform whole genome association studies. Bioinformatics 23(5):644–645PubMedCrossRef
18.
Zurück zum Zitat Lake SL et al (2003) Estimation and tests of haplotype-environment interaction when linkage phase is ambiguous. Hum Hered 55(1):56–65PubMedCrossRef Lake SL et al (2003) Estimation and tests of haplotype-environment interaction when linkage phase is ambiguous. Hum Hered 55(1):56–65PubMedCrossRef
19.
Zurück zum Zitat Lau J, Ioannidis JP, Schmid CH (1997) Quantitative synthesis in systematic reviews. Ann Intern Med 127(9):820–826PubMed Lau J, Ioannidis JP, Schmid CH (1997) Quantitative synthesis in systematic reviews. Ann Intern Med 127(9):820–826PubMed
20.
Zurück zum Zitat Stacey SN et al (2010) Ancestry-shift refinement mapping of the C6orf97-ESR1 breast cancer susceptibility locus. PLoS Genet 6(7):e1001029PubMedCrossRef Stacey SN et al (2010) Ancestry-shift refinement mapping of the C6orf97-ESR1 breast cancer susceptibility locus. PLoS Genet 6(7):e1001029PubMedCrossRef
21.
Zurück zum Zitat Fairbrother WG et al (2002) Predictive identification of exonic splicing enhancers in human genes. Science 297(5583):1007–1013PubMedCrossRef Fairbrother WG et al (2002) Predictive identification of exonic splicing enhancers in human genes. Science 297(5583):1007–1013PubMedCrossRef
Metadaten
Titel
Genetic variants of 6q25 and breast cancer susceptibility: a two-stage fine mapping study in a Chinese population
verfasst von
Jing Han
Tao Jiang
Hongling Bai
Hongru Gu
Jing Dong
Hongxia Ma
Zhibin Hu
Hongbing Shen
Publikationsdatum
01.10.2011
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 3/2011
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-011-1527-x

Weitere Artikel der Ausgabe 3/2011

Breast Cancer Research and Treatment 3/2011 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

ASS schützt nicht vor Brustkrebsrezidiven

02.05.2024 Mammakarzinom Nachrichten

Nützt nichts und ist vielleicht sogar schädlich: In einer Phase-3-Studie konnten täglich 300 mg ASS keine Brustkrebsrezidive bei Frauen vermeiden, die ein hohes Risiko für eine Tumorrückkehr aufwiesen. Tendenziell traten unter ASS sogar häufiger Rezidive auf als unter Placebo.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.